Literature DB >> 12645223

[Malignant peritoneal mesothelioma -- diagnostic and therapeutic difficulties].

P Cunha1, Z Luz, I Seves, C Sousa, L Ribeiro, Costa Marques, M Oliveira.   

Abstract

Malignant Peritoneal Mesothelioma (MPM) is an uncommon tumour. Clinical presentation is indefinite and differential diagnosis with peritoneal carcinomatosis is difficult. It has a bad prognosis (survival of 6-12 months) due to the delay of the diagnosis and inefficacy of the conventional therapeutic. The authors present a case of MPM which was diagnosed over the investigation of ascitis. The laparoscopic peritoneal biopsy permitted the diagnosis. After systemic quimiotherapy, the patient is in partial remission at 42 months of follow-up.

Entities:  

Mesh:

Year:  2002        PMID: 12645223

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  10 in total

1.  Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.

Authors:  Francine Baumann; Erin Flores; Andrea Napolitano; Shreya Kanodia; Emanuela Taioli; Harvey Pass; Haining Yang; Michele Carbone
Journal:  Carcinogenesis       Date:  2014-11-07       Impact factor: 4.944

2.  Predictive factors analysis for malignant peritoneal mesothelioma.

Authors:  Shi Jin; Shoubo Cao; Jingyan Cao; Jing Shen; Jing Hu; Dehai Che; Jiawen Zhang; Yan Yu
Journal:  J Gastrointest Surg       Date:  2014-10-09       Impact factor: 3.452

Review 3.  Peritoneal mesothelioma: a review.

Authors:  Alessio Bridda; Ilaria Padoan; Roberto Mencarelli; Mauro Frego
Journal:  MedGenMed       Date:  2007-05-10

4.  Malignant peritoneal mesothelioma - a rare cause of laparotomy.

Authors:  Tomasz Okniński; Monika Romanowska; Jacek Pawlak; Agnieszka Nawrocka-Kunecka
Journal:  Prz Gastroenterol       Date:  2017-05-30

5.  Peritoneal Malignant Psammomatous Mesothelioma.

Authors:  Teresa Pusiol; Maria Grazia Zorzi; Doriana Morichetti; Irene Piscioli; Michele Scialpi
Journal:  World J Oncol       Date:  2010-08-29

6.  Identification of tumor antigens in malignant mesothelioma.

Authors:  Ye-Rin Kim; Myung-Ha Song; Jun-Won Lee; Jae-Ho Bae; Jong-Eun Kim; Dong-Muk Kang; Sang-Yull Lee
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

7.  Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database.

Authors:  Asad Ullah; Abdul Waheed; Jaffar Khan; Ankita Mishra; Bisma Tareen; Noor Nama; Nabin Raj Karki; Muhammad Saleem Panezai; Luis Velasquez Zarate; Joseph White; Frederick D Cason; Nathaniel Matolo; Subhasis Misra; Nagla Abdel Karim
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

8.  Biphasic Peritoneal Mesothelioma: A Lethal Clinical Entity.

Authors:  Abdul Waheed; Shahin Foroutan; Audrey McCloskey; Harmanprit Randhawa; Frederick D Cason
Journal:  Cureus       Date:  2022-02-26

Review 9.  Malignant mesothelioma.

Authors:  Ishtiaq Ahmed; Salman Ahmed Tipu; Sundas Ishtiaq
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

10.  Co-existing tuberculosis and malignant mesothelioma with multiple sites venous thrombosis: a case report.

Authors:  Pratyush Kumar; Kunal Chawla; Pooja Khosla; Sunil Jain
Journal:  BMC Res Notes       Date:  2016-08-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.